Autolus Therapeutics PLC
NASDAQ:AUTL

Watchlist Manager
Autolus Therapeutics PLC Logo
Autolus Therapeutics PLC
NASDAQ:AUTL
Watchlist
Price: 2.18 USD -4.8% Market Closed
Market Cap: 580.1m USD
Have any thoughts about
Autolus Therapeutics PLC?
Write Note

Operating Margin
Autolus Therapeutics PLC

-1 459.7%
Current
-6 741%
Average
-7.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-1 459.7%
=
Operating Profit
-147.3m
/
Revenue
10.1m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
UK
Autolus Therapeutics PLC
NASDAQ:AUTL
580.1m USD
-1 460%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
315.2B USD
28%
US
Amgen Inc
NASDAQ:AMGN
141.9B USD
19%
US
Gilead Sciences Inc
NASDAQ:GILD
116.4B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
104.5B USD
40%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
135.7B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.7B USD
30%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36B EUR
-22%
Country UK
Market Cap 580.1m USD
Operating Margin
-1 460%
Country FR
Market Cap 6T USD
Operating Margin
-17 527%
Country US
Market Cap 315.2B USD
Operating Margin
28%
Country US
Market Cap 141.9B USD
Operating Margin
19%
Country US
Market Cap 116.4B USD
Operating Margin
38%
Country US
Market Cap 104.5B USD
Operating Margin
40%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Country AU
Market Cap 135.7B AUD
Operating Margin
26%
Country US
Market Cap 78.7B USD
Operating Margin
30%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Country NL
Market Cap 36B EUR
Operating Margin
-22%
No Stocks Found

Autolus Therapeutics PLC
Glance View

Market Cap
580.1m USD
Industry
Biotechnology

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. The firm is focused on developing programmed T cell therapies for the treatment of cancer. The firm has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. Its lead clinical programs include AUTO1 (obecabtagene autoleucel, Obe-Cel), AUTO4, and AUTO6 / AUTO6NG. Obe-cel is a CD19 CAR T cell investigational therapy designed to overcome limitations in clinical activity and safety. Obe-cel reduces toxicity and is less prone to T cell exhaustion, which could improve persistence and the ability of programmed T cells to engage in serial killing of target cancer cells. AUTO4 is a T cell therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1. AUTO6 / AUTO6NG is a T cell therapy targeting GD2 in development for the treatment of neuroblastoma. Its other clinical programs include AUTO5, AUTO7, and AUTO8.

AUTL Intrinsic Value
5.07 USD
Undervaluation 57%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-1 459.7%
=
Operating Profit
-147.3m
/
Revenue
10.1m
What is the Operating Margin of Autolus Therapeutics PLC?

Based on Autolus Therapeutics PLC's most recent financial statements, the company has Operating Margin of -1 459.7%.